Researchers analyzed a case of a 66-year-old patient who was diagnosed with prostate cancer infiltrating the rectum along with solitary rectal metastases that were staged using 18F-PSMA-1007 PET/CT. The whole-body scan was able to detect multiple foci of abnormal tracer uptake in the pelvis and abdomen. The PET/CT and contrast-enhanced computed tomography images showed an increased uptake of radiotracer in primary tumor in residual prostate gland infiltrating the neck of urinary bladder, rectum, levator ani, and obturator muscles with pelvic ...
RLT-PSMA
Advertisement
Latest News
New imaging agent for patients with PSMA-negative PCa shows safety and efficacy among tests in breast cancer patients.
18F-PSMA-1007 can offer more advantages regarding biokinetics and production than the standard tracer 68Ga-PSMA-11.
18F-PSMA-1007 imaging after primary prostate cancer treatment can help detect sites of local tumor relapse.
68Ga-PSMA PET/CT and multiparametric prostate MRIs are compared to see which is more accurate in detection and diagnosis.
Patients with PSA persistence or BCR after RP should be monitored closely to see if they require more PSMA PET scans.
Part two of an interview with Russell Szmulewitz, MD on the benefits of PSMA-PET for high-risk and advanced prostate cancer.
Advertisement
Videos
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Neoadjuvant platinum-based chemotherapy has been found effective for treating metastatic penile squamous cell carcinoma.
A new study has found an association between neurodevelopmental disorders and testicular seminoma.
CLEAR study results showed that treatment with first-line lenvatinib plus pembrolizumab had clinical benefit at 2 years.
The RACE IT trial finds neoadjuvant radio-immunotherapy followed by radical cystectomy a safe and feasible treatment option.
Patients with mCRPC with AR alterations had significantly worse survival outcomes compared with patients with wild-type.
A meta-analysis found that triplet regimens with darolutamide and APP improved survival in mCSPC with high volume of disease.
Advertisement
Advertisement
Expert Discussions
Akhil Saji, MD, interviews Ida Sonni, MD, about using PSMA-PET to better understand recurrence risk and inform therapy plans.
Dr. Saji continues his interview with Dr. Sonni about using PSMA-PET to understand recurrence risk and inform therapy plans.
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
